Questions • challenges • controversies: Use of oral isotretinoin in the management of rosacea

Journal of Clinical and Aesthetic Dermatology

Volumn 4, Issue 9, 2011, Pages

  Park, Hyunhee ^a   Del Rosso, James Q ^b  

^a Center for Clinical and Cosmetic Research   (United States)

^b VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; CALCITRIOL; DOXYCYCLINE; ERYTHROMYCIN; FLUOCINOLONE ACETONIDE; FLUOROURACIL; ISOTRETINOIN; METRONIDAZOLE; PREDNISOLONE; PSORALEN; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID; SULFACETAMIDE; SULFUR;

ACTINIC KERATOSIS; ACTINIC POROKERATOSIS; BASAL CELL CARCINOMA; CONDYLOMA ACUMINATUM; CONFLUENT AND RETICULATED PAPILLOMATOSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY LIPS; EXTRAFACIAL ROSACEA; GRANULOMA; HUMAN; LAMELLAR ICHTHYOSIS; LIP DISEASE; LYMPHOMA; MELANOMA; MUIR TORRE SYNDROME; NOTE; PITYRIASIS RUBRA PILARIS; PSORIASIS; PUVA; QUALITY OF LIFE; RECALCITRANT ROSACEA; ROSACEA; ROSACEA FULMINANS; SKIN LUPUS ERYTHEMATOSUS; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; XEROSIS;

EID: 80755174557     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (79)

1. Orfanos CE, Zouboulis CC, Almond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs. 1997;53:358-388. (Pubitemid 27117359)
2. Nikolowski J, Plewig G. Behandlung der Rosacea mit 13-cis-Retinsaure. Hautarzt. 1981;32:575-584.
3. Nikolowski J, Plewig G, Hofmann C. In-vivo-Test zum Nachweis der antiinflammatorischen Wirkung der 13-cis-Retinsaure. Dermatol Monatsschr. 1982;168:173-181. (Pubitemid 12108759)
4. Akyol M, Ozcelik S. Non-acne dermatologic indications for systemic isotretinoin. Am J Clinc Dermatol. 2005;6(3):175-184. (Pubitemid 40994260)
5. Cardamakis E, Kotoulas LG, Relakis K, et al. Comparative study of systemic interferon alfa-2A plus isotretinoin versus isotretinoin in the treatment of recurrent condyloma acuminatum in men. Urology. 1995;45:857-860.
6. Lambrinos P, Cardamakis E, Michopoulos J, et al. Comparative study of systemic interferon alfa-2a plus isotretinoin vs isotretinoin in the treatment of recurrent condylomata acuminata [abstract]. Gynecol Endocrinol. 1993;17(Suppl 1):109.
7. Piattelli A, Fioroni M, Santinelli A, et al. Bcl-2 expression and apoptotic bodies in 13-cis retinoic acid (isotretinoin) topically treated oral leukoplakia: a pilot study. Oral Oncol. 1999;35:314-20. (Pubitemid 29148366)
8. Moon TE, Levine N, Cartmel B, et al. Retinoids in prevention of skin cancer. Cancer Lett. 1997;114:203-205. (Pubitemid 27140113)
9. DiGiovanna JJ. Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention. Transplant Proc. 1998;30:2881-2885.
10. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition. 2000;16:1084-2090.
11. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
12. Pelle MT, Crawford GH, James WD. Rosaca: II. Therapy. J Am Acad Dermatol. 2004;51(4):499-512.
13. Pye RJ, Burton JL. Treatment of rosacea by metronidazole. Lancet. 1976;1:1211-1212.
14. Guilhou JJ, Meynadier J, Guilhou E, et al. [Treatment of rosacea with metronidazole] (French). Nouv Presse Med. 1978;7:1960-1961.
15. Stieger M. Metronidazole (Flagyl) as a therapy variant in "rosacea" and in "perioral dermatitis" (preliminary report) (German). Z Hautkr. 1979;39:403-405.
16. Arechalde A, Saurat J-H. Management of psoriasis: the position of retinoid drugs. BioDrugs. 2000;13:327-333. (Pubitemid 30399445)
17. Honigsmann H, Wolff K. Isotretinoin-PUVA for psoriasis [letter]. Lancet. 1983;I:236. (Pubitemid 13171114)
18. Sofen EL, Moy RL, Lowe NJ. Treatment of generalized pustular psoriasis with isotretinoin [letter]. Lancet. 1984;7:40. (Pubitemid 14213493)
19. Moy RL, Kingston TP, Lowe NJ. Isotretinoin vs. etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol. 1985;121:1297-1301. (Pubitemid 15248071)
20. Anstey A, Hawk JLM. Isotretinoin-PUVA in women with psoriasis. Br J Dermatol. 1997;136:798-799.
21. Peck GL, Yoder FW, Olsen TG, et al. Treatment of Darier's disease, lamellar ichthyosis, pityriasis rubra pilaris, cystic acne, and basal cell carcinoma with oral 13-cis retinoic acid (isotretinoin). Dermatologica. 1978;157(Suppl 1):11-12. (Pubitemid 9008620)
22. Gilgor RS, Chiaramonti A, Goldsmith LA, et al. Evaluation of 13-cis-retinoic acid in lamellar ichthyosis, pityriasis rubra pilaris and Darier's disease. Cutis. 1980;25:380-385. (Pubitemid 10134109)
23. Risch J, Ashton RE, Lowe N. 13-cis-retinoic acid for dyskeratinizing diseases: clinicopathologic responses. Clin Exp Dermatol. 1984;9:472-483. (Pubitemid 14037167)
24. Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982;6:710-715. (Pubitemid 12147434)
25. Tsambaos D, Georgiou S, Monastirli A, et al. Treatment of condylomata acuminata with oral isotretinoin. J Urol. 1997;158:1810-1812. (Pubitemid 27433158)
26. Olsen EA, Kelly FF, Vollmer RT, et al. Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata. J Am Acad Dermatol. 1989;20:1023-1030. (Pubitemid 19151510)
27. Goldberg L, Hsu S, Alcalay J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol. 1989;21:144-145. (Pubitemid 19171485)
28. Peck GL, DiGiovanni JJ, Sarnoff DS, et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol. 1988;19:176-185.
29. Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinic trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst. 1992;84:328-332.
30. Sander CA, Pfeifer C, Kligman AM, et al. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol. 1997;36:236-238. (Pubitemid 27078918)
31. Majewski S, Skopinska M, Bollag W, et al. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions [letter]. Lancet. 1994;344:1510-1511. (Pubitemid 24351726)
32. Skopinska M, Majewski S, Bolleg W, et al. Calcitriol and isotretinoin combined therapy for precancerous and cancerous skin lesions. J Dermatol Treat. 1997;8:5-10. (Pubitemid 27156777)
33. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis retinoic acid and interferon alpha-2a: effect of combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992;84:241-245.
34. Eisenhauer EA, Lippman SM, Kavanagh JJ, et al. Combination 13-cis retinoic acid and interferon alpha-2a in the therapy of solid tumors. Leukemia. 1994;8:1622-1625. (Pubitemid 24323775)
35. Toma S, Palumbo R, Vincenti M, et al. Efficiency of recombinant alpha-interferon 2a and 13-cis retinoic acid in the treatment of squamous cell carcinoma. Ann Oncol. 1994;5:463-465. (Pubitemid 24159654)
36. Skeel RT, Huang J, Manola J, et al. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). Cancer Invest. 2003;21:41-46. (Pubitemid 36292506)
37. Edwards L, Meyskens F, Levine N. Effect of oral isotretinoin on dysplastic nevi. J Am Acad Dermatol. 1989;20:257-260. (Pubitemid 19055634)
38. Bearzatto A, Orlandi L, Silverstrini R, et al. Combined effects of interferon-alpha2a and 13-cis-retinoic acid on human melanoma cell growth and STAT protein expression. Melanoma Res. 1998;8:31-38. (Pubitemid 28114299)
39. Rosenthal MA, Oratz R. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma. Am J Clin Oncol. 1998;212:352-354. (Pubitemid 28366902)
40. Triozzi PL, Walker MJ, Pellegrini AE, et al. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest. 1996;14:293-298. (Pubitemid 26249165)
41. Kessler JF, Meyskens FL, Levin N, et al. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet. 1983;I(8338):1345-1347. (Pubitemid 13100195)
42. Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate: a study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1987;67:232-236. (Pubitemid 17084985)
43. Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med. 1987;147:529-531. (Pubitemid 17036596)
44. Burg G, Dummer R. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). Clin Lymphoma. 2000;1(Suppl 1):S41-S44.
45. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;34:1022-1029. (Pubitemid 26170769)
46. Schleicher SM, Milstein HJ. Resolution of disseminated granuloma annulare following isotretinoin therapy. Cutis. 1985;36:147-148. (Pubitemid 15248962)
47. Green SG, Piette WW. Successful treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol. 1987;17:364-368. (Pubitemid 17128933)
48. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol. 1991;24:49-52.
49. Lee MP, Stiller MJ, McClain SA, et al. Confluent and reticulated papillomatosis: response to high-dose oral isotretinoin therapy and reassessment of epidemiologic data. J Am Acad Dermatol. 1994;31:327-331. (Pubitemid 24249259)
50. Baden HP, Buxman MM, Weinstein GD, et al. Treatment of ichthyosis with isotretinoin. J Am Acad Dermatol. 1982;6(4 Pt 2 Suppl):716-720. (Pubitemid 12147435)
51. Spielvogel RL, DeVillez RL, Roberts LC. Oral isotretinoin therapy for familial Muir-Torre syndrome. J Am Acad Dermatol. 1985;12:475-480. (Pubitemid 15144632)
52. Graefe T, Wollina U, Schulz H, et al. Muir-Torre syndrome: treatment with isotretinoin and interferon alpha-2a can prevent tumor development. Dermatology. 2000;200:331-333. (Pubitemid 30451584)
53. Schmidt JB, Gebhart W, Raff M, Spona J. 13-cis-Retinoic acid in rosacea. Clinical and laboratory findings. Acta Derm Venereol. 1984;64:15-21. (Pubitemid 14179561)
54. Plewig G, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol. 1982;6:766-785.
55. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986;25:660-663. (Pubitemid 17210593)
56. Marsden JR, Shuster S, Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol. 1984;9:484-488. (Pubitemid 14037168)
57. Gajardo J. Severe rosacea treated with oral isotretinoin. Rev Med Chil. 1994;122(2):177-179.
58. Erdogan FG, Yurtsever P, Aksoy D, et al. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1996;34:1022-1029.
59. Rebora A. The management of rosacea. Am J Clin Dermatol. 2002;3:489-496. (Pubitemid 35007066)
60. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986;25:660-663. (Pubitemid 17210593)
61. Irvine C, Kumar P, Marks R. Isotretinoin in the treatment of rosacea and rhinophyma. In: Marks R, Plewig G, eds. Acne and Related Disorders: Proceedings of an International Symposium. London: Martin Dunitz; 1988:301-305.
62. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F. Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol. 1998;134:88405.
63. Lloyd KM. Surgical correction of rhinophyma. Arch Dermatol. 1990;126:721-723. (Pubitemid 20193785)
64. Jansen T, Plewig G. Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities. Facial Plast Surg. 1998;14:241-253. (Pubitemid 29474183)
65. Gollnick H, Blume-Peytavi U, Szabo EL, et al. Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebocontrolled, randomized clinical study. J Dtsch Dermatol Ges. 2010;8(7):505-515.
66. Hofer T. Continuous "microdose" isotretinoin in adult recalcitrant rosacea. Clin Exp Dermatol. 2004;29(2):204-205. (Pubitemid 38367214)
67. Firooz A, Firoozabadi MR, Doelati Y. Rosacea fulminans (pyoderma faciale): successful treatment of a 3-year old girl with oral isotretinoin. Int J Dermatol. 2001;40(3):203-205. (Pubitemid 32586283)
68. Rosen T, Unkefer RP. Treatment of pyoderma faciale with isotretinoin in a patient with ulcerative colitis. Cutis. 1999;64(2):107- 109.
69. Cunliffe WJ, Rowell NR: Pyoderma faciale. Br J Dermatol. 1987;117(Suppl 32):96-97.
70. Marks VJ, Briggaman RA. Pyoderma faciale: successful treatment with isotretinoin. J Am Acad Dermatol. 1987;17:1062-1063.
71. McHenry PM, Hudson M, Smart LM, et al. Pyoderma faciale in a patient with Crohn's disease. Clin Exp Dal. 1992;17:460-462.
72. Thomas K, Yelverton CB, Yentzer BA, et al. The cost-effectiveness of rosacea treatments. J Dermatolog Treat. 2009;20(2):72- 75.
73. Balkrishnan R, McMichael AJ, Hu YU, et al. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol. 2006;45:111-115.
74. Nicholson K, Abramova L, Chren MM, et al. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol. 2007;57:213-221. (Pubitemid 47053981)
75. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130(3):319-324. (Pubitemid 24107870)
76. Bostanci O, Borelli C, Schaller M. Treatment of extrafacial rosacea with low-dose isotretinoin. Acta Derm Venereol. 2010;90(4):409-410.
77. Ayres S Jr. Extrafacial rosacea is rare but does exist. J Am Acad Dermatol. 1987;16:391-392.
78. Dupont C. How common is extrafacial rosacea? J Am Acad Dermatol. 1986;14:839.
79. Pereira TM, Vieira AP, Basto AS. Rosacea with extensive extrafacial lesions. Int J Dermatol. 2008;47:52-55.